4.2 Article

Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban

Journal

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
Volume 44, Issue 1, Pages 163-167

Publisher

WILEY
DOI: 10.1111/ijlh.13692

Keywords

apixaban; chromogenic assay; DOAC; factor Xa inhibitors; LC-MS; MS; LMWH; rivaroxaban

Categories

Ask authors/readers for more resources

The study evaluated the use of an LMWH-calibrated anti-factor Xa assay in estimating FXa-DOAC concentration, and found that the recalculated concentrations were comparable to those measured by LC-MS/MS. It is suggested that this method can provide guidance on apixaban and rivaroxaban concentrations in acute settings with shorter turnaround time and greater availability compared to traditional methods.
Introduction Direct oral anticoagulant (DOAC)-inhibiting factor Xa (FXa-DOAC) are being increasingly used as prophylaxis of venous thromboembolism and for prevention of stroke in patients with atrial fibrillation. In contrast to vitamin K antagonists, DOACs do not require monitoring in general. However, it is sometimes of value in the acute setting, for instance when considering a reversal agent in uncontrolled bleeding in patients on DOAC. Methods We evaluated if a low-molecular weight heparin (LMWH)-calibrated anti-factor Xa assay could be used to estimate FXa-DOAC concentration in the concentration range <100 ng/mL by spiking known concentrations of FXa-DOAC and from those result calculate the FXa-DOAC concentration from the response of the LMWH assay. This procedure was then evaluated by comparing the result with a drug-calibrated chromogenic assay and liquid chromatography tandem mass spectrometry (LC-MS/MS) on clinical plasma samples from patients treated with apixaban or rivaroxaban. Results Although the measuring range was narrower for the LMWH-calibrated assay, concentrations recalculated from the LMWH assay was comparable with those measured by the drug-calibrated method when compared with LC-MS/MS. Conclusion We suggest that an LMWH-calibrated anti-factor Xa assay can be used after characterization of the response of FXa-DOACs to give guidance on the concentration of apixaban and rivaroxaban. Shorter turnaround time than LC-MS/MS and the greater availability than drug-calibrated chromogenic assays could make this a valuable option in the acute setting.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available